Women with PMOS should get subsidised weight-loss drugs, Australian advocates say
With GLP-1s to treat the condition not specifically approved by the TGA, patients are being prescribed them off-label
-
Get our breaking news email, free app or daily news podcast
Women living with a chronic hormonal condition should have access to taxpayer-funded weight-loss medications, advocates say.
The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.
Share this article
←
Previous Article
New spate of stabbings, overdoses and fires at Australian immigration detention centres run by ICE-linked US prison firm
Next Article
Flydubai co-pilot began radicalisation in Australia, UAE prosecutors say
→
Local News View All →
Australia does not ‘need or want Russian fuel’, Chris Bowen says, after Trump deal to buy diesel from Putin
October 10, 2026
Flydubai co-pilot began radicalisation in Australia, UAE prosecutors say
October 10, 2026
Women with PMOS should get subsidised weight-loss drugs, Australian advocates say
October 9, 2026
